InSite Vision to Host Investor Conference Call Introducing New CEO Timothy Ruane

InSite Vision to Host Investor Conference Call Introducing New CEO Timothy Ruane

ALAMEDA, Calif.--(BUSINESS WIRE)--Dec 8, 2010 - InSite Vision Incorporated (OTCBB:INSV) announced today that the company will host a conference call on Thursday, December 9, 2010 beginning at 4:30 p.m. ET/1:30 p.m. PT to introduce the company's newly appointed Chief Executive Officer, Timothy Ruane. Following Mr. Ruane's remarks, management will respond to questions from the financial community.

"InSite Vision today has a solid foundation of assets, which include our proprietary technology platform, deep pipeline of promising therapeutics, two revenue-producing commercial partnerships and a committed and highly experienced team," said Mr. Ruane. "I am delighted to join InSite Vision at this time and look forward to building value for our shareholders through the advancement of important new ophthalmic therapeutics."

Analysts and investors can participate in the conference call by dialing (877) 407-8035 for domestic callers and (201) 689-8035 for international callers. A telephone replay will be available following the conclusion of the call by dialing (877) 660-6853 for domestic callers and (201) 612-7415 for international callers. All callers will need to enter the account number 286 and conference ID 362529. The live conference call will also be webcast and available on the Investor Relations page of the company's website at www.insitevision.com.

About InSite Vision

InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The company's product portfolio utilizes InSite Vision's proven DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Inspire Pharmaceuticals, and BesivanceTM (besifloxacin ophthalmic suspension) 0.6%, marketed by InSite Vision's licensee Bausch & Lomb and their partner Pfizer Inc. InSite Vision's clinical-stage ophthalmic product pipeline includes ISV-502 and ISV-305 for the treatment of eye infections, and ISV-303 for pain and swelling associated with ocular surgery. For further information on InSite Vision, please visit www.insitevision.com.

 

Contact: InSite Vision
Louis Drapeau, 510-747-1220
Chief Financial Officer
[email protected]
or
BCC Partners
Michelle Corral, 415-794-8662
Media and Investor Inquiries

 

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.